TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5%
Thu, 25 Jul

TORRENT PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

TORRENT PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-18*
3
Mar-19*
3
Jun-19*
QoQ ChangeYoY Change
Net SalesRs m18,72018,56020,2208.9%8.0%
Other incomeRs m27017020017.6%-25.9%
TurnoverRs m18,99018,73020,4209.0%7.5%
ExpensesRs m13,95013,83014,8107.1%6.2%
Gross profitRs m4,7701,1605,410366.4%13.4%
DepreciationRs m1,5001,6001,6000.0%6.7%
InterestRs m1,2201,2301,220-0.8%0.0%
Profit before taxRs m2,320-1,5002,79020.3%
TaxRs m690206303050.0%-8.7%
Profit after taxRs m1,630-1,5202,16032.5%
Gross profit margin%25.56.326.8
Effective tax rate%29.7-1.322.6
Net profit margin%8.6-8.110.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 8.0% on a year-on-year (YoY) basis. The expenses were up by 6.2% YoY during the same period.
  • The company's operating profit increased by 13.4% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 26.8% in 1QFY20 as against 25.5% in 1QFY19.
  • Depreciation charges increased by 6.7% and finance costs increased by 0.0% YoY, respectively.
  • Other income declined by 25.9% YoY during the quarter.
  • Net profit for the quarter increased by 32.5% YoY. Net profit margins during the quarter increased from 8.6% in 1QFY19 to 10.6% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 8.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 7.1% QoQ during the same period.
  • The company's operating profit increased by 366.4% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 26.8% in 1QFY20 as against 6.3% in 4QFY19.
  • Net profit for the quarter increased by 242.1% QoQ, while net profit margins increased from -8.1% in 4QFY19 to 10.6% in 1QFY20.

To see how TORRENT PHARMA has performed over the last eight quarters,please visit here.

TORRENT PHARMA Share Price Performance

Over the last one year,TORRENT PHARMA share price has moved up from Rs 1,476.0 to Rs 1,599.2, registering a Gain of Rs 123.2 or around 8.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,781.6 (up 1.2%). Over the last one year it has moved down from 13,910.0 to 12,781.6, a gain of 1,128 points (down 8.1%).

Overall, the S&P BSE SENSEX is up 3.3% over the year.

Current Valuations

At the current price of Rs 1,599.2, the price to earnings (P/E) ratio of TORRENT PHARMA stands at 55.4 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 5.9 times.

Equitymaster requests your view! Post a comment on "TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5%". Click here!

  

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 1, 2020 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ADCOCK INGRAM COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS